-
1
-
-
84941624753
-
Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, Committee EG. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8-30.
-
(2015)
Ann Oncol
, vol.26
, pp. v8-v30
-
-
Senkus, E.1
Kyriakides, S.2
Ohno, S.3
Penault-Llorca, F.4
Poortmans, P.5
Rutgers, E.6
Zackrisson, S.7
Cardoso, F.8
Committee, E.G.9
-
2
-
-
84897865171
-
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature
-
Drukker CA, van den Hout HC, Sonke GS, Brain E, Bonnefoi H, Cardoso F, Goldhirsch A, Harbeck N, Honkoop AH, Koornstra RH, et al. Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. Eur J Cancer. 2014;50(6):1045-54.
-
(2014)
Eur J Cancer
, vol.50
, Issue.6
, pp. 1045-1054
-
-
Drukker, C.A.1
Hout, H.C.2
Sonke, G.S.3
Brain, E.4
Bonnefoi, H.5
Cardoso, F.6
Goldhirsch, A.7
Harbeck, N.8
Honkoop, A.H.9
Koornstra, R.H.10
-
4
-
-
84898863103
-
Promoting quality and evidence-based care in early-stage breast cancer follow-up
-
dju034
-
Henry NL, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst. 2014;106(4):dju034.
-
(2014)
J Natl Cancer Inst
, vol.106
, Issue.4
-
-
Henry, N.L.1
Hayes, D.F.2
Ramsey, S.D.3
Hortobagyi, G.N.4
Barlow, W.E.5
Gralow, J.R.6
-
5
-
-
84887563411
-
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
-
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15(5):R92.
-
(2013)
Breast Cancer Res
, vol.15
, Issue.5
, pp. R92
-
-
Eccles, S.A.1
Aboagye, E.O.2
Ali, S.3
Anderson, A.S.4
Armes, J.5
Berditchevski, F.6
Blaydes, J.P.7
Brennan, K.8
Brown, N.J.9
Bryant, H.E.10
-
6
-
-
84950291848
-
Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development
-
Stahel R, Bogaerts J, Ciardiello F, de Ruysscher D, Dubsky P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart M et al. Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treat Rev. 2014.
-
(2014)
Cancer Treat Rev
-
-
Stahel, R.1
Bogaerts, J.2
Ciardiello, F.3
de Ruysscher, D.4
Dubsky, P.5
Ducreux, M.6
Finn, S.7
Laurent-Puig, P.8
Peters, S.9
Piccart, M.10
-
7
-
-
84883325272
-
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013
-
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013;24(9):2206-23.
-
(2013)
Annals of oncology: official journal of the European Society for Medical Oncology/ESMO
, vol.24
, Issue.9
, pp. 2206-2223
-
-
Goldhirsch, A.1
Winer, E.P.2
Coates, A.S.3
Gelber, R.D.4
Piccart-Gebhart, M.5
Thurlimann, B.6
Senn, H.J.7
Panel, M.8
-
8
-
-
78649825336
-
Current and emerging biomarkers in breast cancer: prognosis and prediction
-
Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245-62.
-
(2010)
Endocr Relat Cancer
, vol.17
, Issue.4
, pp. R245-R262
-
-
Weigel, M.T.1
Dowsett, M.2
-
9
-
-
84893584450
-
Current approaches and challenges in monitoring treatment responses in breast cancer
-
Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, Stojadinovic A, et al. Current approaches and challenges in monitoring treatment responses in breast cancer. J Cancer. 2014;5(1):58-68.
-
(2014)
J Cancer
, vol.5
, Issue.1
, pp. 58-68
-
-
Graham, L.J.1
Shupe, M.P.2
Schneble, E.J.3
Flynt, F.L.4
Clemenshaw, M.N.5
Kirkpatrick, A.D.6
Gallagher, C.7
Nissan, A.8
Henry, L.9
Stojadinovic, A.10
-
10
-
-
84887963281
-
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
-
Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. Med Oncol. 2014;31(1):776.
-
(2014)
Med Oncol
, vol.31
, Issue.1
, pp. 776
-
-
Petrelli, F.1
Barni, S.2
-
11
-
-
84892943547
-
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation
-
Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract. 2014;20(1):11-28.
-
(2014)
J Oncol Pharm Pract
, vol.20
, Issue.1
, pp. 11-28
-
-
Chung, C.1
Christianson, M.2
-
12
-
-
84886093926
-
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer
-
Rutherford T, Orr J Jr, Grendys E Jr, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, et al. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol. 2013;131(2):362-7.
-
(2013)
Gynecol Oncol
, vol.131
, Issue.2
, pp. 362-367
-
-
Rutherford, T.1
Orr, J.2
Grendys, E.3
Edwards, R.4
Krivak, T.C.5
Holloway, R.6
Moore, R.G.7
Puls, L.8
Tillmanns, T.9
Schink, J.C.10
-
13
-
-
84869502207
-
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
-
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342-54.
-
(2012)
Eur J Cancer
, vol.48
, Issue.18
, pp. 3342-3354
-
-
Houssami, N.1
Macaskill, P.2
Minckwitz, G.3
Marinovich, M.L.4
Mamounas, E.5
-
14
-
-
70349448551
-
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer
-
Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg. 2009;198(4):520-5.
-
(2009)
Am J Surg
, vol.198
, Issue.4
, pp. 520-525
-
-
Tan, M.C.1
Al Mushawah, F.2
Gao, F.3
Aft, R.L.4
Gillanders, W.E.5
Eberlein, T.J.6
Margenthaler, J.A.7
-
15
-
-
84874984779
-
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
-
Angelucci D, Tinari N, Grassadonia A, Cianchetti E, Ausili-Cefaro G, Iezzi L, Zilli M, Grossi S, Ursini LA, Scognamiglio MT, et al. Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. J Cancer Res Clin Oncol. 2013;139(2):269-80.
-
(2013)
J Cancer Res Clin Oncol
, vol.139
, Issue.2
, pp. 269-280
-
-
Angelucci, D.1
Tinari, N.2
Grassadonia, A.3
Cianchetti, E.4
Ausili-Cefaro, G.5
Iezzi, L.6
Zilli, M.7
Grossi, S.8
Ursini, L.A.9
Scognamiglio, M.T.10
-
16
-
-
84908893016
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
-
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacon JI, Parker JS, Calvo L, Plazaola A, Arcusa A, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer. 2014;111(8):1532-41.
-
(2014)
Br J Cancer
, vol.111
, Issue.8
, pp. 1532-1541
-
-
Prat, A.1
Lluch, A.2
Albanell, J.3
Barry, W.T.4
Fan, C.5
Chacon, J.I.6
Parker, J.S.7
Calvo, L.8
Plazaola, A.9
Arcusa, A.10
-
17
-
-
84889050826
-
Circulating tumor cells in HER2- positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
-
Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, Li S, Hu Z, Wu S, Liu B, et al. Circulating tumor cells in HER2- positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer. 2013;13:202.
-
(2013)
BMC Cancer
, vol.13
, pp. 202
-
-
Liu, Y.1
Liu, Q.2
Wang, T.3
Bian, L.4
Zhang, S.5
Hu, H.6
Li, S.7
Hu, Z.8
Wu, S.9
Liu, B.10
-
18
-
-
70349929431
-
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
-
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA: J Am Med Assoc. 2009;302(13):1429-36.
-
(2009)
JAMA: J Am Med Assoc
, vol.302
, Issue.13
, pp. 1429-1436
-
-
Schroth, W.1
Goetz, M.P.2
Hamann, U.3
Fasching, P.A.4
Schmidt, M.5
Winter, S.6
Fritz, P.7
Simon, W.8
Suman, V.J.9
Ames, M.M.10
-
19
-
-
84918591788
-
Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer
-
Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20(23):5995-6005.
-
(2014)
Clin Cancer Res
, vol.20
, Issue.23
, pp. 5995-6005
-
-
Brown, J.R.1
Wimberly, H.2
Lannin, D.R.3
Nixon, C.4
Rimm, D.L.5
Bossuyt, V.6
-
20
-
-
84920368791
-
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer
-
Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, JH O, Carpenter J, Storniolo AM, et al. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56(1):31-7.
-
(2015)
J Nucl Med
, vol.56
, Issue.1
, pp. 31-37
-
-
Connolly, R.M.1
Leal, J.P.2
Goetz, M.P.3
Zhang, Z.4
Zhou, X.C.5
Jacobs, L.K.6
Mhlanga, J.7
Carpenter, J.8
Storniolo, A.M.9
-
21
-
-
84924270342
-
Multigene prognostic tests in breast cancer: past, present, future
-
Gyorffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17:11.
-
(2015)
Breast Cancer Res.
, vol.17
, pp. 11
-
-
Gyorffy, B.1
Hatzis, C.2
Sanft, T.3
Hofstatter, E.4
Aktas, B.5
Pusztai, L.6
-
23
-
-
84862303759
-
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
-
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-804.
-
(2012)
J Clin Oncol
, vol.30
, Issue.15
, pp. 1796-1804
-
-
Minckwitz, G.1
Untch, M.2
Blohmer, J.U.3
Costa, S.D.4
Eidtmann, H.5
Fasching, P.A.6
Gerber, B.7
Eiermann, W.8
Hilfrich, J.9
Huober, J.10
-
24
-
-
84876691969
-
Ten-year analysis of the prospective multicentre chemo-n0 trial validates American Society Of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
-
Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, et al. Ten-year analysis of the prospective multicentre chemo-n0 trial validates American Society Of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013;49(8):1825-35.
-
(2013)
Eur J Cancer
, vol.49
, Issue.8
, pp. 1825-1835
-
-
Harbeck, N.1
Schmitt, M.2
Meisner, C.3
Friedel, C.4
Untch, M.5
Schmidt, M.6
Sweep, C.G.7
Lisboa, B.W.8
Lux, M.P.9
Beck, T.10
-
25
-
-
73249140371
-
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
-
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
-
(2010)
Lancet Oncol
, vol.11
, Issue.1
, pp. 55-65
-
-
Albain, K.S.1
Barlow, W.E.2
Shak, S.3
Hortobagyi, G.N.4
Livingston, R.B.5
Yeh, I.T.6
Ravdin, P.7
Bugarini, R.8
Baehner, F.L.9
Davidson, N.E.10
-
26
-
-
0141566685
-
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
-
Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003;9(11):4227-39.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.11
, pp. 4227-4239
-
-
Voskoglou-Nomikos, T.1
Pater, J.L.2
Seymour, L.3
-
27
-
-
84899726499
-
Use of rodents as models of human diseases
-
Vandamme TF. Use of rodents as models of human diseases. J Pharm Bioallied Sci. 2014;6(1):2-9.
-
(2014)
J Pharm Bioallied Sci
, vol.6
, Issue.1
, pp. 2-9
-
-
Vandamme, T.F.1
-
28
-
-
33645736793
-
Genetically engineered models have advantages over xenografts for preclinical studies
-
Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 2006;66(7):3355-8 (discussion 3358-3359).
-
(2006)
Cancer Res
, vol.66
, Issue.7
, pp. 3355-3358
-
-
Becher, O.J.1
Holland, E.C.2
-
30
-
-
84907053777
-
Mouse models of human cancer
-
Bock BC, Stein U, Schmitt CA, Augustin HG. Mouse models of human cancer. Cancer Res. 2014;74(17):4671-5.
-
(2014)
Cancer Res
, vol.74
, Issue.17
, pp. 4671-4675
-
-
Bock, B.C.1
Stein, U.2
Schmitt, C.A.3
Augustin, H.G.4
-
32
-
-
84893637270
-
One mouse, one patient paradigm: new avatars of personalized cancer therapy
-
Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344(1):1-12.
-
(2014)
Cancer Lett
, vol.344
, Issue.1
, pp. 1-12
-
-
Malaney, P.1
Nicosia, S.V.2
Dave, V.3
-
33
-
-
33845209913
-
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
-
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27.
-
(2006)
Cancer Cell
, vol.10
, Issue.6
, pp. 515-527
-
-
Neve, R.M.1
Chin, K.2
Fridlyand, J.3
Yeh, J.4
Baehner, F.L.5
Fevr, T.6
Clark, L.7
Bayani, N.8
Coppe, J.P.9
Tong, F.10
-
34
-
-
79960015997
-
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
-
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750-67.
-
(2011)
J Clin Investig
, vol.121
, Issue.7
, pp. 2750-2767
-
-
Lehmann, B.D.1
Bauer, J.A.2
Chen, X.3
Sanders, M.E.4
Chakravarthy, A.B.5
Shyr, Y.6
Pietenpol, J.A.7
-
35
-
-
34248650697
-
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression
-
Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2007;1(1):84-96.
-
(2007)
Mol Oncol
, vol.1
, Issue.1
, pp. 84-96
-
-
Kenny, P.A.1
Lee, G.Y.2
Myers, C.A.3
Neve, R.M.4
Semeiks, J.R.5
Spellman, P.T.6
Lorenz, K.7
Lee, E.H.8
Barcellos-Hoff, M.H.9
Petersen, O.W.10
-
36
-
-
84947237670
-
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors
-
Cifani P, Kirik U, Waldemarson S, James P. Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors. J Proteome Res. 2015;14(7):2819-27.
-
(2015)
J Proteome Res
, vol.14
, Issue.7
, pp. 2819-2827
-
-
Cifani, P.1
Kirik, U.2
Waldemarson, S.3
James, P.4
-
37
-
-
0345700343
-
Breast cancer cell lines: friend or foe?
-
Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003;5(2):89-95.
-
(2003)
Breast Cancer Res
, vol.5
, Issue.2
, pp. 89-95
-
-
Burdall, S.E.1
Hanby, A.M.2
Lansdown, M.R.3
Speirs, V.4
-
38
-
-
84940759331
-
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening.
-
Theodoraki MA, Rezende CO Jr., Chantarasriwong O, Corben AD, Theodorakis EA, Alpaugh ML. Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening. Oncotarget. 2015.
-
(2015)
Oncotarget.
-
-
Theodoraki, M.A.1
Rezende, C.O.2
Chantarasriwong, O.3
Corben, A.D.4
Theodorakis, E.A.5
Alpaugh, M.L.6
-
39
-
-
84937043995
-
Impact of the spheroid model complexity on drug response.
-
Hoffmann OI, Ilmberger C, Magosch S, Joka M, Jauch KW, Mayer B. Impact of the spheroid model complexity on drug response. J Biotechnol. 2015.
-
(2015)
J Biotechnol.
-
-
Hoffmann, O.I.1
Ilmberger, C.2
Magosch, S.3
Joka, M.4
Jauch, K.W.5
Mayer, B.6
-
40
-
-
84915752568
-
Personalized in vitro cancer modeling-fantasy or reality?
-
Bartlett R, Everett W, Lim S, Natasha G, Loizidou M, Jell G, Tan A, Seifalian AM. Personalized in vitro cancer modeling-fantasy or reality? Transl Oncol. 2014;7(6):657-64.
-
(2014)
Transl Oncol
, vol.7
, Issue.6
, pp. 657-664
-
-
Bartlett, R.1
Everett, W.2
Lim, S.3
Natasha, G.4
Loizidou, M.5
Jell, G.6
Tan, A.7
Seifalian, A.M.8
-
41
-
-
84891404742
-
Organoid cultures for the analysis of cancer phenotypes
-
Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev. 2014;24:68-73.
-
(2014)
Curr Opin Genet Dev
, vol.24
, pp. 68-73
-
-
Sachs, N.1
Clevers, H.2
-
42
-
-
84905674530
-
Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment.
-
Herrmann D, Conway JR, Vennin C, Magenau A, Hughes WG, Morton JP, Timpson P. Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. Carcinogenesis. 2014.
-
(2014)
Carcinogenesis.
-
-
Herrmann, D.1
Conway, J.R.2
Vennin, C.3
Magenau, A.4
Hughes, W.G.5
Morton, J.P.6
Timpson, P.7
-
43
-
-
84870569410
-
Three-dimensional culture of human breast epithelial cells: the how and the why
-
Vidi PA, Bissell MJ, Lelievre SA. Three-dimensional culture of human breast epithelial cells: the how and the why. Methods Mol Biol. 2013;945:193-219.
-
(2013)
Methods Mol Biol
, vol.945
, pp. 193-219
-
-
Vidi, P.A.1
Bissell, M.J.2
Lelievre, S.A.3
-
44
-
-
16544380146
-
The use of 3-D cultures for high-throughput screening: the multicellular spheroid model
-
Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen. 2004;9(4):273-85.
-
(2004)
J Biomol Screen
, vol.9
, Issue.4
, pp. 273-285
-
-
Kunz-Schughart, L.A.1
Freyer, J.P.2
Hofstaedter, F.3
Ebner, R.4
-
45
-
-
84892406857
-
Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery
-
Evensen NA, Li J, Yang J, Yu X, Sampson NS, Zucker S, Cao J. Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery. PLoS One. 2013;8(12):e82811.
-
(2013)
PLoS One
, vol.8
, Issue.12
, pp. e82811
-
-
Evensen, N.A.1
Li, J.2
Yang, J.3
Yu, X.4
Sampson, N.S.5
Zucker, S.6
Cao, J.7
-
46
-
-
79960001863
-
Effects of affinity on binding of HER2-targeting Affibody molecules: model experiments in breast cancer spheroids
-
Qvarnstrom OF, Simonsson M, Carlsson J, Tran TA. Effects of affinity on binding of HER2-targeting Affibody molecules: model experiments in breast cancer spheroids. Int J Oncol. 2011;39(2):353-9.
-
(2011)
Int J Oncol
, vol.39
, Issue.2
, pp. 353-359
-
-
Qvarnstrom, O.F.1
Simonsson, M.2
Carlsson, J.3
Tran, T.A.4
-
47
-
-
0023579733
-
In vitro chemosensitivity testing using the multicellular tumor spheroid model
-
Kerr DJ, Wheldon TE, Kerr AM, Kaye SB. In vitro chemosensitivity testing using the multicellular tumor spheroid model. Cancer Drug Deliv. 1987;4(2):63-74.
-
(1987)
Cancer Drug Deliv
, vol.4
, Issue.2
, pp. 63-74
-
-
Kerr, D.J.1
Wheldon, T.E.2
Kerr, A.M.3
Kaye, S.B.4
-
48
-
-
84904008768
-
Engineering mammary gland in vitro models for cancer diagnostics and therapy
-
Campbell JJ, Hume RD, Watson CJ. Engineering mammary gland in vitro models for cancer diagnostics and therapy. Mol Pharm. 2014;11(7):1971-81.
-
(2014)
Mol Pharm
, vol.11
, Issue.7
, pp. 1971-1981
-
-
Campbell, J.J.1
Hume, R.D.2
Watson, C.J.3
-
49
-
-
79952264003
-
Multicellular spheroids as an in vitro model in experimental oncology: applications in translational medicine
-
Khaitan D, Dwarakanath BS. Multicellular spheroids as an in vitro model in experimental oncology: applications in translational medicine. Expert Opin Drug Discov. 2006;1(7):663-75.
-
(2006)
Expert Opin Drug Discov
, vol.1
, Issue.7
, pp. 663-675
-
-
Khaitan, D.1
Dwarakanath, B.S.2
-
50
-
-
77953916745
-
Multicellular tumor spheroids: an underestimated tool is catching up again
-
Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148(1):3-15.
-
(2010)
J Biotechnol
, vol.148
, Issue.1
, pp. 3-15
-
-
Hirschhaeuser, F.1
Menne, H.2
Dittfeld, C.3
West, J.4
Mueller-Klieser, W.5
Kunz-Schughart, L.A.6
-
51
-
-
84937034223
-
Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy-the SpheroNEO study
-
Halfter K, Ditsch N, Kolberg HC, Fischer H, Hauzenberger T, von Koch FE, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, et al. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy-the SpheroNEO study. BMC Cancer. 2015;15:519.
-
(2015)
BMC Cancer
, vol.15
, pp. 519
-
-
Halfter, K.1
Ditsch, N.2
Kolberg, H.C.3
Fischer, H.4
Hauzenberger, T.5
Koch, F.E.6
Bauerfeind, I.7
Minckwitz, G.8
Funke, I.9
Crispin, A.10
-
52
-
-
0015762456
-
A human cell line from a pleural effusion derived from a breast carcinoma
-
Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51(5):1409-16.
-
(1973)
J Natl Cancer Inst
, vol.51
, Issue.5
, pp. 1409-1416
-
-
Soule, H.D.1
Vazguez, J.2
Long, A.3
Albert, S.4
Brennan, M.5
-
53
-
-
0018764332
-
Establishment and characterization of a cell line of human breast carcinoma origin
-
Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S, Brenner HJ. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer. 1979;15(5):659-70.
-
(1979)
Eur J Cancer
, vol.15
, Issue.5
, pp. 659-670
-
-
Keydar, I.1
Chen, L.2
Karby, S.3
Weiss, F.R.4
Delarea, J.5
Radu, M.6
Chaitcik, S.7
Brenner, H.J.8
-
54
-
-
0031739560
-
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer
-
Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998;78(6):766-74.
-
(1998)
Int J Cancer
, vol.78
, Issue.6
, pp. 766-774
-
-
Gazdar, A.F.1
Kurvari, V.2
Virmani, A.3
Gollahon, L.4
Sakaguchi, M.5
Westerfield, M.6
Kodagoda, D.7
Stasny, V.8
Cunningham, H.T.9
Wistuba, I.I.10
-
55
-
-
0032146256
-
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier
-
Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 1998;58(15):3237-42.
-
(1998)
Cancer Res
, vol.58
, Issue.15
, pp. 3237-3242
-
-
Tomlinson, G.E.1
Chen, T.T.2
Stastny, V.A.3
Virmani, A.K.4
Spillman, M.A.5
Tonk, V.6
Blum, J.L.7
Schneider, N.R.8
Wistuba, I.I.9
Shay, J.W.10
-
56
-
-
84934970026
-
Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer
-
Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience. 2015;9:518.
-
(2015)
Ecancermedicalscience
, vol.9
, pp. 518
-
-
Esposito, A.1
Criscitiello, C.2
Curigliano, G.3
-
57
-
-
84900458585
-
Breast cancer version 3.2014
-
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014;12(4):542-90.
-
(2014)
J Natl Compr Canc Netw
, vol.12
, Issue.4
, pp. 542-590
-
-
Gradishar, W.J.1
Anderson, B.O.2
Blair, S.L.3
Burstein, H.J.4
Cyr, A.5
Elias, A.D.6
Farrar, W.B.7
Forero, A.8
Giordano, S.H.9
Goldstein, L.J.10
-
58
-
-
77951629946
-
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
-
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28(12):2015-23.
-
(2010)
J Clin Oncol
, vol.28
, Issue.12
, pp. 2015-2023
-
-
Minckwitz, G.1
Rezai, M.2
Loibl, S.3
Fasching, P.A.4
Huober, J.5
Tesch, H.6
Bauerfeind, I.7
Hilfrich, J.8
Eidtmann, H.9
Gerber, B.10
-
59
-
-
0019217348
-
In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer
-
Kaufmann M, Klinga K, Runnebaum B, Kubli F. In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer. Eur J Cancer. 1980;16(12):1609-13.
-
(1980)
Eur J Cancer
, vol.16
, Issue.12
, pp. 1609-1613
-
-
Kaufmann, M.1
Klinga, K.2
Runnebaum, B.3
Kubli, F.4
-
60
-
-
84904188903
-
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
-
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014.
-
(2014)
Lancet.
-
-
Cortazar, P.1
Zhang, L.2
Untch, M.3
Mehta, K.4
Costantino, J.P.5
Wolmark, N.6
Bonnefoi, H.7
Cameron, D.8
Gianni, L.9
Valagussa, P.10
-
61
-
-
84953637912
-
Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K
-
Lahsaee S, Corkery DP, Anthes LE, Holly A, Dellaire G. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. Exp Cell Res. 2016;340(1):125-31.
-
(2016)
Exp Cell Res
, vol.340
, Issue.1
, pp. 125-131
-
-
Lahsaee, S.1
Corkery, D.P.2
Anthes, L.E.3
Holly, A.4
Dellaire, G.5
-
62
-
-
84931332357
-
Evaluation of chemotherapeutics in a three-dimensional breast cancer model
-
Lovitt CJ, Shelper TB, Avery VM. Evaluation of chemotherapeutics in a three-dimensional breast cancer model. J Cancer Res Clin Oncol. 2015;141(5):951-9.
-
(2015)
J Cancer Res Clin Oncol
, vol.141
, Issue.5
, pp. 951-959
-
-
Lovitt, C.J.1
Shelper, T.B.2
Avery, V.M.3
-
63
-
-
84930616832
-
Time-lapse imaging assay using the BioStation CT: a sensitive drug-screening method for three-dimensional cell culture
-
Sakamoto R, Rahman MM, Shimomura M, Itoh M, Nakatsura T. Time-lapse imaging assay using the BioStation CT: a sensitive drug-screening method for three-dimensional cell culture. Cancer Sci. 2015;106(6):757-65.
-
(2015)
Cancer Sci
, vol.106
, Issue.6
, pp. 757-765
-
-
Sakamoto, R.1
Rahman, M.M.2
Shimomura, M.3
Itoh, M.4
Nakatsura, T.5
-
64
-
-
84924076132
-
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
-
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71.
-
(2015)
Ann Oncol
, vol.26
, Issue.2
, pp. 259-271
-
-
Salgado, R.1
Denkert, C.2
Demaria, S.3
Sirtaine, N.4
Klauschen, F.5
Pruneri, G.6
Wienert, S.7
Eynden, G.8
Baehner, F.L.9
Penault-Llorca, F.10
-
65
-
-
84887042578
-
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
-
Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24(11):2786-93.
-
(2013)
Ann Oncol
, vol.24
, Issue.11
, pp. 2786-2793
-
-
Denkert, C.1
Loibl, S.2
Muller, B.M.3
Eidtmann, H.4
Schmitt, W.D.5
Eiermann, W.6
Gerber, B.7
Tesch, H.8
Hilfrich, J.9
Huober, J.10
-
66
-
-
84964696930
-
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
-
Garcia-Martinez E, Gil GL, Benito AC, Gonzalez-Billalabeitia E, Conesa MA, Garcia Garcia T, Garcia Garcia E, Vicente V, Ayala de la Pena F. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488.
-
(2014)
Breast Cancer Res
, vol.16
, Issue.6
, pp. 488
-
-
Garcia-Martinez, E.1
Gil, G.L.2
Benito, A.C.3
Gonzalez-Billalabeitia, E.4
Conesa, M.A.5
Garcia Garcia, T.6
Garcia Garcia, E.7
Vicente, V.8
de la Pena, A.F.9
-
67
-
-
73949092850
-
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
-
Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-13.
-
(2010)
J Clin Oncol
, vol.28
, Issue.1
, pp. 105-113
-
-
Denkert, C.1
Loibl, S.2
Noske, A.3
Roller, M.4
Muller, B.M.5
Komor, M.6
Budczies, J.7
Darb-Esfahani, S.8
Kronenwett, R.9
Hanusch, C.10
-
68
-
-
84951908548
-
A prospective comparison of the 21-gene recurrence score and the pam50-based prosigna in estrogen receptor-positive early-stage breast cancer.
-
Alvarado MD, Prasad C, Rothney M, Cherbavaz DB, Sing AP, Baehner FL, Svedman C, Markopoulos CJ. A prospective comparison of the 21-gene recurrence score and the pam50-based prosigna in estrogen receptor-positive early-stage breast cancer. Adv Ther. 2015.
-
(2015)
Adv Ther.
-
-
Alvarado, M.D.1
Prasad, C.2
Rothney, M.3
Cherbavaz, D.B.4
Sing, A.P.5
Baehner, F.L.6
Svedman, C.7
Markopoulos, C.J.8
-
69
-
-
84908160897
-
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial
-
Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast. 2014;23(5):656-62.
-
(2014)
Breast
, vol.23
, Issue.5
, pp. 656-662
-
-
Llombart-Cussac, A.1
Pivot, X.2
Biganzoli, L.3
Cortes-Funes, H.4
Pritchard, K.I.5
Pierga, J.Y.6
Smith, I.7
Thomssen, C.8
Srock, S.9
Sampayo, M.10
-
70
-
-
84923673213
-
Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments
-
Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep. 2015;17(4):15.
-
(2015)
Curr Oncol Rep
, vol.17
, Issue.4
, pp. 15
-
-
Stover, D.G.1
Wagle, N.2
-
71
-
-
58149330982
-
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
-
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
-
(2008)
Breast Cancer Res
, vol.10
, Issue.4
, pp. R65
-
-
Wirapati, P.1
Sotiriou, C.2
Kunkel, S.3
Farmer, P.4
Pradervand, S.5
Haibe-Kains, B.6
Desmedt, C.7
Ignatiadis, M.8
Sengstag, T.9
Schutz, F.10
-
72
-
-
84927551836
-
Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
-
Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15:138.
-
(2015)
BMC Cancer
, vol.15
, pp. 138
-
-
Bae, S.Y.1
Kim, S.2
Lee, J.H.3
Lee, H.C.4
Lee, S.K.5
Kil, W.H.6
Kim, S.W.7
Lee, J.E.8
Nam, S.J.9
-
73
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
-
(2005)
Lancet
, vol.365
, Issue.9472
, pp. 1687-1717
-
-
|